Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Clin Cancer Res. 2008 Nov 15;14(22):7340–7347. doi: 10.1158/1078-0432.CCR-08-0642

Figure 3. Simultaneous inhibition of HDAC6 and proteasome activity induces synergistic killing of ovarian cancer cells.

Figure 3

Dose-dependent inhibition of the cell viability of ES-2 (A) and TOV-21G (B) in the absence (−) or in the presence (+) of 5μM NK84 HDAC6 inhibitor and PS-341 at the indicated concentration. Cell viability was measured after a 24 hours incubation by XTT assay and the percentage of viable cells is presented relative to mock-treated controls. ***P < 0.001. Error bars indicate ± SD. Lysate of ES-2 cell line treated with NK84 (5 μm) and/or PS-341 at the indicated concentrations was immunoblotted with an antibody recognizing the full-length and cleaved forms of PARP. Equal protein loading was verified by using an antibody directed against β-actin.